


## MID-1

<b>Cat. No.:</b>	HY-115461		
<b>CAS No.:</b>	312608-54-1		
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>11</sub> N <sub>3</sub> O <sub>4</sub> S		
<b>Molecular Weight:</b>	293.3		
<b>Target:</b>	Insulin Receptor		
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 31.25 mg/mL (106.55 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	3.4095 mL	17.0474 mL	34.0948 mL
		5 mM	0.6819 mL	3.4095 mL	6.8190 mL
10 mM		0.3409 mL	1.7047 mL	3.4095 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (7.09 mM); Suspended solution; Need ultrasonic				

## BIOLOGICAL ACTIVITY

<b>Description</b>	MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake <sup>[1]</sup> .
<b>In Vitro</b>	<p>MID-1 (5 μM; 24 h) increases the IRS-1 expression level in skeletal muscle by disrupting the MG53-IRS-1 interaction<sup>[1]</sup>.</p> <p>MID-1 (10 μM; 12 h) reduces the luciferase activity in HEK 293 cell line expressing NLUC-IRS-1 and CLUC-C14A<sup>[1]</sup>.</p> <p>MID-1 (1-20 μM; 12 h) disrupts the MG53-IRS-1 interaction but not MG53-FAK interaction in HEK 293 cells<sup>[1]</sup>.</p> <p>MID-1 (0.1-10 μM; 4-24 h) abolishes MG53-induced IRS-1 ubiquitination and degradation in HEK 293 cells<sup>[1]</sup>.</p> <p>MID-1 (5-10 μM; 24 h) increases insulin signaling and insulin-elicited glucose uptake in C2C12 myotubes<sup>[1]</sup>.</p> <p>MID-1 (5-10 μM; 24 h) enhances skeletal myogenesis<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p>

	<table border="1"><tr><td>Cell Line:</td><td>C2C12 myotubes</td></tr><tr><td>Concentration:</td><td>5 <math>\mu</math>M</td></tr><tr><td>Incubation Time:</td><td>24 h</td></tr><tr><td>Result:</td><td>Increased the IRS-1 protein level.</td></tr></table>	Cell Line:	C2C12 myotubes	Concentration:	5 $\mu$ M	Incubation Time:	24 h	Result:	Increased the IRS-1 protein level.
Cell Line:	C2C12 myotubes								
Concentration:	5 $\mu$ M								
Incubation Time:	24 h								
Result:	Increased the IRS-1 protein level.								
<b>In Vivo</b>	MID-1 does not have good pharmacokinetics in vivo <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								

## REFERENCES

[1]. Lee H, et, al. MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) Interaction Disruptor Sensitizes Insulin Signaling in Skeletal Muscle. J Biol Chem. 2016 Dec 23;291(52):26627-26635.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA